文献速递围术期管理与 ERAS急腹症与外科感染

抗血小板治疗对非心脏手术出血并发症影响的荟萃分析

A Meta-analysis of the Impact of Aspirin, Clopidogrel, and Dual Antiplatelet Therapy on Bleeding Complications in Noncardiac Surgery.
PubMed 文献 · Ann Surg · 2018-01-01

该系统综述与荟萃分析纳入46项研究、超过3万例患者,评估阿司匹林、氯吡格雷及双联抗血小板治疗(DAPT)对比安慰剂或不治疗在非心脏手术中的出血风险。结果显示阿司匹林(RR 1.14)和DAPT(RR 1.33)输血风险轻度升高,但需再干预的出血风险无显著增加,血栓并发症无差异。

要点

  • 阿司匹林增加输血风险(RR 1.14),DAPT增加更明显(RR 1.33)。
  • 需再干预的出血风险各抗血小板药物均无显著升高。
  • 心肌梗死、卒中及死亡率与对照相比无差异。

核心结论

  • 非心脏手术时抗血小板治疗出血风险较小,血栓并发症无差异。
  • 对于有明确指征的患者,多数情况下继续抗血小板治疗是安全的。

研究设计与样本

  • 系统综述与荟萃分析,检索同行评议文献及会议摘要。
  • 排除无对照组或仅研究冠脉支架患者的研究,最终纳入46项研究。
  • 荟萃分析纳入超过30,000例患者,比较单药或DAPT与安慰剂或不治疗。

主要发现

  • 输血相对风险:阿司匹林 vs 对照为1.14(95%CI 1.03-1.26,P=0.009)。
  • 输血相对风险:DAPT vs 对照为1.33(95%CI 1.15-1.55,P=0.001)。
  • 氯吡格雷输血风险升高,但数据异质性过大未行荟萃分析。
  • 需再干预的出血相对风险:阿司匹林0.96(0.76-1.22,P=0.76),氯吡格雷1.84(0.87-3.87,P=0.11),DAPT 1.51(0.92-2.49,P=0.1)。
  • 心肌梗死RR 1.06(0.79-1.43),卒中RR 0.97(0.71-1.33),死亡率RR 0.97(0.87-1.1),均无显著差异。

关键数值与推荐

  • 主要终点为输血和因出血需再干预。
  • 胸腹部手术亚组分析结果相似。

临床怎么用

  • 对有重要抗血小板治疗指征的患者,非心脏手术期间可考虑继续用药。
  • 需权衡输血风险轻度增加与血栓事件风险无差异,个体化决策。

局限性

  • 氯吡格雷数据异质性过大,未能进行荟萃分析。
  • 纳入会议摘要可能影响证据质量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study was to determine the bleeding risks associated with single (aspirin) and dual (aspirin + clopidogrel) antiplatelet therapy (DAPT) versus placebo or no treatment in adults undergoing noncardiac surgery. SUMMARY OF BACKGROUND DATA: The impact of antiplatelet therapy on bleeding during noncardiac surgery remains controversial. A meta-analysis was performed to examine the risk associated with single and DAPT. METHODS: A systematic review of antiplatelet therapy, noncardiac surgery, and perioperative bleeding was performed. Peer-reviewed sources and meeting abstracts from relevant societies were queried. Studies without a control group, or those that only examined patients with coronary stents, were excluded. Primary endpoints were transfusion and reintervention for bleeding. RESULTS: Of 11,592 references, 46 studies met inclusion criteria. In a meta-analysis of >30,000 patients, the relative risk (RR) of transfusion versus control was 1.14 [95% confidence interval (CI) 1.03-1.26, P = 0.009] for aspirin, and 1.33 (1.15-1.55, P = 0.001) for DAPT. Clopidogrel had an elevated risk, but data were too heterogeneous to analyze. The RR of bleeding requiring reintervention was not significantly higher for any agent compared to control [RR 0.96 (0.76-1.22, P = 0.76) for aspirin, 1.84 (0.87-3.87, P = 0.11) for clopidogrel, and 1.51 (0.92-2.49, P = 0.1) for DAPT]. Subanalysis of thoracic and abdominal procedures was similar. There was no difference in RR for myocardial infarction [1.06 (0.79-1.43)], stroke [0.97 (0.71-1.33)], or mortality [0.97 (0.87-1.1)]. CONCLUSIONS: Antiplatelet therapy at the time of noncardiac surgery confers minimal bleeding risk with no difference in thrombotic complications. In many cases, it is safe to continue antiplatelet therapy in patients with important indications for their use.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Columbo JA, Lambour AJ, Sundling RA, et al. A Meta-analysis of the Impact of Aspirin, Clopidogrel, and Dual Antiplatelet Therapy on Bleeding Complications in Noncardiac Surgery. Ann Surg. 2018. PMID: 28463896. doi:10.1097/SLA.0000000000002279

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。